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Prion diseases and dental treatment: principles and
practice of patients with/suspected or at-risk of
CJD: Case reports 
A. J. Smith,1 M. P. Sweeney2 and J Bagg3
The emergence of variant CJD (vCJD) in the last decade has heightened awareness of the need for rigorous infection control
precautions in all healthcare environments. It has also raised particular problems in relation to the clinical management of
patients who are either suffering from prion diseases or who are perceived as being ‘at risk’. From the healthcare perspective
CJD is of concern because at present it is an incurable, fatal disease and the causative agent, abnormal prion protein, is
resistant to conventional inactivation procedures. Many healthcare workers are concerned about the risks of cross-infection
when treating such patients. There are a number of guidelines for the management of CJD patients, though the information
they provide sometimes appears contradictory and may require some interpretation in the clinical setting. This paper is based
on real-life case scenarios and the advice given to dentists for the management of a group of patients with different
manifestations of prion diseases. 
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INTRODUCTION
In 2000, the Department of Health estab-
lished the CJD advice network. This group
comprises individuals from a wide range of
healthcare professions and volunteer work-
ers with experience in the management and
treatment of patients with CJD. The aim of
the network is to share the experiences of
the management of patients with CJD with
other healthcare professionals. There are a
number of dentally qualified individuals on
the network to provide support and advice
to the dental profession on the management
of patients with CJD. Since the network was
established there have been over 20 cases
where advice has been sought on the dental
management of patients with CJD, those
with suspected CJD or those ‘at-risk’ of CJD. 
Prion diseases may present as infectious,
genetic or sporadic forms of the disease
(Table 1). It is important to have a con-
firmed diagnosis of the type of CJD from
which the patient is suffering, since this
may affect future treatment of family mem-
bers of the case. Prion diseases are invari-
ably fatal, frequently with a rapid decline in
health, particularly in the latter stages of
the disease. However, the main challenge
from the infection control perspective is
that the agents primarily responsible for
CJD, abnormal prions, are remarkably
resistant to conventional sterilization
processes. Current evidence suggests that
normal social or routine clinical contact
does not present a risk to healthcare work-
ers, families or others. There is no evidence
of infectivity in saliva1-3 and there is uncer-
tainty about the potential for transmission
from blood, but universal infection control
precautions should minimise any risk that
may exist. 
There are a number of guidelines3-5 for
the management of patients with confirmed
CJD, those suspected of suffering from CJD
and those ‘at-risk’ of CJD. The definition of
the ‘at-risk’ group is shown in Table 2. 
The aim of this paper is to describe the
infection control protocols recommended
for actual dental treatment in a range of
patients in these groups.
● This paper describes the case management of several cases of patients with confirmed CJD,
suspected CJD or ‘at-risk’ from CJD.
● Background infection control information relevant to CJD is provided.
● Practical advice is given on the clinical management of patients with CJD.
I N  B R I E F
Table 1 Different types of Human CJD
Mode of acquisition of CJD Type of CJD
Sporadic Sporadic CJD
Inherited Familial CJD
Acquired — Human Kuru, iatrogenic CJD 
Acquired — Bovine Variant CJD
Table 2 Definition of ‘at-risk’ patients
Definition of ‘at-risk’ = Asymptomatic but
potentially at-risk of developing disease:
-recipients of hormone derived from human
pituitary glands eg growth hormone, gonadotrophin.
-recipients of human dura mater grafts
-people with a close (blood line) family history of
CJD.
Source: Advisory Committee on Dangerous Pathogens and
Spongiform Encephalopathy Advisory Committee (1998).
Transmissible Spongiform Encephalopathy agents: Safe
working and the prevention of infection. London, Stationery
Office.
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SCENARIO 1 — A PROBABLE CASE OF VCJD
Patient A had been recently diagnosed
with probable vCJD. The unit caring for
the patient wished to formulate a protocol
for dental treatment of the patient should
it become necessary. Unfortunately the
patient died prior to the provision of any
dental treatment. However, pre-planning
is essential and the recommendations
which were given for treatment were as
follows. 
Case management
It is unlikely that general dental practi-
tioners will be directly involved in the
provision of care for patients suffering,
or suspected to be suffering, from any
form of CJD. Such patients may be
exhibiting early neurological signs and
symptoms of disease and their care will
be mostly based in a hospice or hospital.
Appropriate treatment planning for this
group of patients is best performed by
dentists with experience of special care
dentistry.
Because of the rarity and special fea-
tures of the disease, local care services,
including dental professionals, may need
specialist support and advice. The main co-
ordinating source of advice is the National
CJD Surveillance Unit (NCJDSU). The
NCJDSU based at the Western General Hos-
pital, Edinburgh, has a national care co-
ordinator to provide specialist expertise in
CJD and to act as an information resource
for carers and professionals.
All patients with a clinical diagnosis of
CJD should have a named key worker
identified to co-ordinate care for patient
and family, regardless of the setting in
which care is given. It is vital that appro-
priate members of the dental team are
involved at an early stage to provide
advice and, if necessary, treatment for the
patient. Key workers should be aware of
the importance of preventive dental
advice as part of the overall care of such
patients. All healthcare professionals
should be alert to the rapidity of deterio-
ration that occurs in CJD and reassess
patients’ needs frequently. Of note for
dentists is the presence of neurological
deficits, such as sensory and motor
impairments, which may manifest in the
head and neck region. Such features may
present such as atypical facial pain.
Treatment guidelines have been sug-
gested6 for the management of confirmed
and suspected CJD cases. There is one
major difference from normal universal
infection control procedures, namely the
requirement for all instruments, includ-
ing handpieces, to be single-use in those
cases where the diagnosis is confirmed.
This may entail a period of quarantining
instruments whilst the diagnosis is being
made. In all other respects, the manage-
ment of confirmed or suspected cases of
CJD for routine dental procedures
requires no special infection control pre-
cautions for operator or patient above the
universal infection control precautions
adopted for all patients. Some authors
have suggested additional precautions for
this group of patients, such as a separate
water supply for handpieces and suction
systems.7 However, this has not been uni-
versally accepted,8 since there is no evi-
dence to suggest that prions are transmit-
ted via this route. Clearly, protocols for
the disposal of non single-use devices
such as handpieces must be considered
before treatment, in conjunction with the
local infection control team. Forward
planning, both logistical and financial,
are essential.
SCENARIO 2 — A RELATIVE OF A PATIENT
WITH VCJD
Patient B attended his / her regular GDP
with a complaint of toothache. During the
course of the examination the patient con-
firmed that a close family relative had died
from vCJD. The GDP performed emergency
dental treatment to relieve the dental
source of the pain. At the conclusion of the
visit the GDP placed all the re-usable den-
tal equipment in a secure box and instruct-
ed the patient to take the instruments home
in the event that further dental treatment
may be required.
Case management
Guidance on the management of family
members of patients who are suffering or
have died from vCJD has, in the past, been
confusing. As a result, some family mem-
bers have been refused treatment by their
general dental practitioner, community
dental services and hospital dental units.
Recent advice has clarified that family
members of vCJD cases do not require any
additional infection control precautions.5
Following discussion with the general
dental practitioner of patient B, the instru-
ments used to treat the patient were
returned to the practice and reprocessed
according to the normal routine. The
patient continues to attend the general
dental practitioner for routine dental treat-
ment with no special infection control pre-
cautions.
SCENARIO 3 – AN ELDERLY NURSING
HOME RESIDENT WITH SUSPECTED CJD
A community dental officer was asked to
review Patient C, an elderly individual with
a suspected diagnosis of sporadic CJD, who
had a broken denture. Following examina-
tion of the patient a decision was made to
repair the denture, but advice was sought
on suitable infection control measures.
Case management
There is no evidence of infectivity in saliva
for either human or animal prion
diseases.1-3 Adherence to universal infec-
tion control precautions is sufficient to
minimise the risks from abnormal prions
or any other infectious disease likely to be
encountered in this environment. The
infection control advice for the replace-
ment of patient C’s denture followed rou-
tine protocols of impression taking fol-
lowed by a thorough rinsing of the
impression under running tap water and
soaking for 5 minutes in a freshly prepared
solution of a proprietary dental impression
disinfectant. The denture laboratory was
informed and reassured. The denture was
repaired and returned to the patient.
SCENARIO 4 — A PATIENT ‘AT-RISK’ OF CJD
Following a routine medical history check,
patient D revealed that he / she had
received artificial growth hormone as a
child during the 1970s. This information
would classify the patient as ‘at risk’ for
iatrogenic CJD. No urgent dental treat-
ment was required and the general dental
practitioner sought advice on infection
control precautions for this patient.
Case management
The management of patients in the ‘at-risk’
group is controversial, with a number of
guidelines providing advice.3-5 Some of the
guidelines recommend stringent instru-
ment decontamination procedures,3 which
are difficult to implement in most general
dental practices. In this particular case, ref-
erence was made to the World Health
Organisation (WHO) guidelines4 on the
management of patients ‘at-risk’ of CJD.
In summary, the decision was made that
for routine dental procedures, which the
WHO guidelines currently regard as low
risk in relation to potential transmission of
abnormal prion protein, no special infec-
tion control procedures were necessary for
the treatment of this patient. The re-pro-
cessing of re-usable dental instruments,
such as, high speed handpieces and hand
instruments, was performed according to
the usual surgery protocol of cleaning and
sterilising in a bench top autoclave at the
standard time and temperature settings. In
addition, advice was given to the general
dental practitioner that reprocessing of
endodontic files was not recommended
and that these instruments should be for
single patient use only. In the light of cur-
rent evidence on the difficulty of cleaning
endodontic instruments,9 it is the authors’
view that they should be viewed as single
use for all patients, regardless of their
medical history.
If the WHO guidelines4 are accepted
and followed for the management of ‘at
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risk’ patients, then it removes the need to
seek information in the medical history
relating to previous injections of pituitary
hormones, placement of dura mater grafts
and family history of CJD. This is the cur-
rent policy at Glasgow Dental Hospital and
at the practice providing care for patient D.
However, a high standard of infection con-
trol must be applied for all patients, with
particular emphasis on cleaning of re-
usable devices prior to sterilisation and
care to ensure that no single-use items are
re-processed.
DISCUSSION
The emergence of CJD in the last decade
has heightened awareness of the need for
thorough infection control procedures,
not just for confirmed or suspected cases
of CJD but for all patients in a number of
healthcare environments. The current
advice from the Department of Health fol-
lowing a risk assessment of the risks of
transmission of vCJD via surgical instru-
ments is that the effectiveness of routine
instrument decontamination should be of
the highest standard to minimise the risks
of onward transmission.10 Whilst current
data suggest that prion proteins cannot be
detected in pulpal tissue from patients
with sporadic CJD,11 it is unknown
whether the agent of vCJD is present in
dental pulps. There is an additional com-
plication because the agent of vCJD is also
present in lymphoid tissue,12 with possi-
ble implications for transmission during
certain oral and dental procedures. There
is animal model work that suggests the
potential for onward transmission of
scrapie agent via the dental route in a
hamster model,13 though direct extrapola-
tion to human forms of CJD is difficult,
due to differences in the strain of prion
protein used and the experimental host.
There are a number of guidelines avail-
able from national and international advi-
sory bodies which provide advice on the
management of patients affected by CJD.
These guidelines have been compiled in
the face of relatively little direct clinical,
epidemiological or experimental evi-
dence, especially in relation to vCJD. This
can lead to difficulties in establishing
treatment protocols for affected patients,
with many healthcare workers delaying or
refusing to provide treatment because of
fears over cross-infection. The case stud-
ies provided in this paper present practical
and pragmatic advice that was used for
the management of four cases, to high-
light the range of presentations of patients
presenting with prion diseases. However,
this is a rapidly moving area and these
case studies do not provide the definitive
answer to case management, which may
be modified in the light of new informa-
tion. The cases do, however, illustrate that
up to date advice is available from a num-
ber of sources, a selection of which is pro-
vided below. In addition, practitioners
should be aware that they can liase with
their local infection control teams to
assess the risks from each case and devise
local protocols in the light of current
guidelines for the management of patients
with CJD. Patients with prion diseases,
together with their families, have over-
whelming medical, social and psychologi-
cal problems. Dental health problems only
add to that burden and the dental profes-
sion can play a very important role in
alleviating such difficulties when they
arise.
1. Hadlow W J, Kennedy R C, Race R E. Natural infection
of Suffolk sheep with scrapie virus. J Infect Dis 1982;
146: 657-664.
2. Brown P, Gibbs C J Jr, Rodgers-Johnson P, et al.
Human spongiform encephalopathy: the National
Institute of Health series of 300 cases of
experimentally transmitted disease. Ann Neurol 1994;
35: 513-29.
3. Advisory Committee on Dangerous Pathogens and
Spongiform Encephalopathy Advisory Committee
(1998). Transmissible Spongiform Encephalopathy
agents: Safe working and the prevention of infection.
London, Stationery Office. 
4. WHO/CDS/APH/2000.3 WHO infection control
guidelines for transmissible spongiform
encephalopathies.
(www.who.int/csr/resources/publications/bse/WHO_
CDS_CSR_APH_2000_3/en/)
5. Department of Health (2000): Creutzfeldt-Jacob
disease: Guidance for healthcare workers.
(www.doh.gov.uk/cjd/healthworkers.htm)
6. Smith A J, Sweeney M P. Oral Health for patients with
CJD. Briefing sheet 7.
(http://www.hbsef.org/brief7andrewsmithdentist.htm)
7. Porter S, Scully,C, Ridgway G L, Bell J. The human
transmissible spongiform encephalopathies (TSEs):
implications for dental practitioners. Br Dent J 2000;
188: 432-436.
8. Smith A J, Martin M V. Managing patients with TSE’s.
Br Dent J 2000; 189: 62.
9. Smith A J, Bagg J, Aitken J, Dickson M. Contaminated
dental instruments. J Hosp Infect 2002; 51: 233-235.
10. Department of Health. Risk assessment for
transmission of vCJD via surgical instruments: A
modelling approach and numerical scenarios (2001)
(www.doh.gov.uk/cjd/riskassessmentsi.htm). 
11. Blanquet-Grossard F, Sazdovitch V, Jean A, et al. Prion
protein is not detectable in dental pulp from patients
with Creutzfeldt-Jakob disease. J Dent Res 2000; 79:
700.
12. Hill A F, Butterworth R J, Joiner S, et al. Investigation
of variant Creutzfeldt-Jakob disease and other
human prion diseases with tonsil biopsy samples.
Lancet 1999; 353: 183-189.
13. Ingrosso L, Pisani F, Pocchiari M. Transmission of the
263K scrapie strain by the dental route. J Gen Virol
1999; 80: 3043-3047.
Sources of further advice
1. National Care Co-ordinator for CJD
Gordon McLean,
National CJD Surveillance Unit,
Western General Hospital,
Crewe Road,
Edinburgh.
Tel: 0131 537 2129
www.cjd.ed.ac.uk
2. CJD Support Network
Gillian Turner
National CJD Co-ordinator
CJD Support Network
Birchwood
Heath Top
Ashley Heath
Market Drayton,
Shropshire
Tel: 01630 673 993
www.cjdsupport.net
email: info@cjdsupport.net
3. Department of Health CJD advice network
A virtual network of a wide range of healthcare
workers who have had experience of treating patients
with CJD. They can be contacted via the CJD support
network. The network includes two dentists, one of
whom is a general dental practitioner.
4. The Prion Unit
Prion Unit,
Dept of Neurology,
St Mary’s hospital,
Praed St,
London
Tel: 0207 886 6883
The Prion Unit at St Mary’s Hospital, London. Provides
assessment, diagnosis and on-going support for
patients suffering from CJD.
5. The Human BSE Foundation
Tel 0191 389 4157
www.hbsef.org
A voluntary organisation run by families of vCJD
patients aimed at helping relatives, friends and carers
of vCJD patients. 
Addendum
Following submission of this publication the Department of Health has recently
published updated guidance for healthcare workers on safe working with transmissible
spongiform encephalopathies (TSEs) such as Creutzfeldt-Jakob Disease (CJD). This
guidance replaces the edition issued in March 1998 and are published on-line at
www.doh.gov.uk/cjd/tseguidance.
The revised guidelines recognise the low risk of transmission of infection from dental
instruments, provided that optimal standards of infection control and decontamination
are maintained. In practice this means that instruments used on all patients in the ‘at-
risk’ category can be treated in the same manner as those for all other patients. This
recommendation is also extended to routine dentistry in confirmed or suspected CJD
cases, negating the requirement to destroy or quarantine instruments. These guidelines
re-inforce the notion that any patient or their relatives may be treated in general dental
practice (in the same manner as any member of the general public). The logical extension
of these guidelines removes the necessity to identify patients in the ‘at-risk’ category
when taking a medical history prior to dental treatment. It will be clear to readers that
these new guidelines would have simplified and expedited the management of the four
patients described in this paper.
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